Goldman Sachs Remains a Buy on Pro Medicus Limited (PMCUF)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 13 2025
0mins
Source: Business Insider
Analyst Ratings: Annabel Li from Goldman Sachs maintains a Buy rating on Pro Medicus Limited with a price target of A$309.00, while the general analyst consensus suggests a Hold rating with an average price target of $163.74, indicating a potential downside.
Financial Performance: Pro Medicus reported strong quarterly earnings with revenue of $87.39 million and a net profit of $46.54 million, showing significant growth compared to the previous year, but insider sentiment has turned negative with increased selling activity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
